2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid

We are 2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid CAS:763114-26-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid
CAS.NO: 763114-26-7
Synonyms:
2-fluoro-5-[(4-oxo-3H-phthalazin-1-yl)methyl]benzoic acid

Molecular Formula:C16H11FN2O3
Molecular Weight: 298.26900

Physical and Chemical Properties:
Density: 1.42 g/cm3
Boiling point: /
Melting point:/
Flash point: /
Refractive index: /

Specification:
Appearance:Pink yellow solid
Purity:≥98%
Impurity: <0.3%
Loss on drying:≤0.1% 
Moisture Content: <0.2%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:
Intermediates of Olaparib CAS:763113-22-0

Related News: The program caused the price of some drugs to plunge more than 90% when it was introduced last year in some cities, state news agency Xinhua said.4-butilresorcinol CAS:18979-61-8 Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,” said Mark Corbett, EVP, Inceptua Medicines Access.4-Aminobenzotrifluoride CAS:455-14-1 Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,” said Mark Corbett, EVP, Inceptua Medicines Access.(3-chlorophenyl)-(3,4-dimethoxyphenyl)methanone CAS:116412-84-1 Physiologically relevant interactions with test molecules or protein ligands can be identified with high sensitivity and specificity.An analysis of the top 20 global companies by R&D spend for 2018 shows that companies with expensive late-stage pipeline drugs are spending significant proportions of their annual revenue on R&D.